BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 35931181)

  • 21. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis.
    Srivastava A; Nogueras Gonzalez GM; Geng Y; Won AM; Cabanillas ME; Naing A; Myers JN; Li Y; Chambers MS
    Support Care Cancer; 2021 May; 29(5):2305-2317. PubMed ID: 33190182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
    Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
    J Formos Med Assoc; 2021 Aug; 120(8):1572-1580. PubMed ID: 33309430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M; Kuroshima S; Sawase T
    Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
    Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
    Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.
    Sobczak-Jaskow H; KochaƄska B; Drogoszewska B
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374277
    [No Abstract]   [Full Text] [Related]  

  • 26. In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review.
    Guirguis RH; Tan LP; Hicks RM; Hasan A; Duong TD; Hu X; Hng JYS; Hadi MH; Owuama HC; Matthyssen T; McCullough M; Canfora F; Paolini R; Celentano A
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.
    Matsumoto A; Sasaki M; Schmelzeisen R; Oyama Y; Mori Y; Voss PJ
    Clin Oral Investig; 2017 Jan; 21(1):127-134. PubMed ID: 26924135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.
    Jung S; Kim J; Park JH; Kim KY; Kim HJ; Park W
    Sci Rep; 2022 May; 12(1):8641. PubMed ID: 35606457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Type of Antiresorptive Treatment Influences the Time to Onset and the Surgical Outcome of Medication-Related Osteonecrosis of the Jaw.
    Pautke C; Wick A; Otto S; Hohlweg-Majert B; Hoffmann J; Ristow O
    J Oral Maxillofac Surg; 2021 Mar; 79(3):611-621. PubMed ID: 33166522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy.
    Halpern LR; Adams DR
    Dent Clin North Am; 2024 Jan; 68(1):67-85. PubMed ID: 37951638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management.
    Chan BH; Yee R; Puvanendran R; Ang SB
    Singapore Med J; 2018 Feb; 59(2):70-75. PubMed ID: 29568850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab.
    Wick A; Bankosegger P; Otto S; Hohlweg-Majert B; Steiner T; Probst F; Ristow O; Pautke C
    Clin Oral Investig; 2022 Mar; 26(3):2839-2852. PubMed ID: 34812959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
    Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?
    Colella A; Yu E; Sambrook P; Hughes T; Goss A
    J Oral Maxillofac Surg; 2023 Feb; 81(2):232-237. PubMed ID: 36442534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw.
    Obermeier KT; Dewenter I; Malenova Y; Fliefel R; Kaeppler G; Otto S
    Sci Rep; 2024 Apr; 14(1):7914. PubMed ID: 38575664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing the Surgical Response of Bisphosphonate-Related Versus Denosumab-Related Osteonecrosis of the Jaws.
    Palla B; Burian E; Deek A; Scott C; Anderson J; Callahan N; Carlson ER
    J Oral Maxillofac Surg; 2021 May; 79(5):1045-1052. PubMed ID: 33358707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
    Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
    Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
    Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
    Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.